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Abstract
Background: The cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) are innate cellular factors that inhibit
replication of a number of viruses, including HIV-1. Since antiviral activity of APOBEC3 has been mainly confirmed
by in vitro data, we examined their role for disease progression in the SIV/macaque model for AIDS.
Results: We quantified A3G and A3F mRNA in PBMC and leukocyte subsets of uninfected and SIVmac-infected
rhesus macaques. Compared with uninfected animals, we found increased A3G and A3F mRNA levels in PBMC,
purified CD4+ T-cells and CD14+ monocytes as well as lymph node cells from asymptomatic SIV-infected
macaques. APOBEC3 mRNA levels correlated negatively with plasma viral load, and highest amounts of APOBEC3
mRNA were detected in long term non-progressors (LTNPs). During acute viremia, A3G mRNA increased in parallel
with MxA, a prototype interferon-stimulated gene indicating a common regulation by the initial interferon
response. This association disappeared during the asymptomatic stage.
Conclusion: Our findings suggest a protective effect of APOBEC3 for HIV and SIV in vivo and indicate regulation of
APOBEC3 by interferon during early infection and by contribution of other, hitherto undefined factors at later
disease stages. Elucidating the regulatory mechanisms leading to increased APOBEC3 mRNA levels in LTNPs could
help to develop new therapies against HIV.
Background
Infection with HIV leads to the development of severe
immunodeficiency in a widely variable time frame. A small
percentage of the HIV-infected individuals, the long term
non-progressors (LTNPs) even remain clinically healthy
without symptoms for over 15 years [1]. Those differences
are thought to result from the interaction of virus and
host factors influencing viral replication. Two recently
described innate host factors in humans, APOBEC3G
(hA3G) and APOBEC3F (hA3F), possess antiretroviral
activity and have been shown to restrict HIV-1 replication
in vitro [2-4]. In the absence of the HIV-1 accessory
protein Vif, hA3G and hA3F are incorporated into virus
particles and impair retroviral replication by introducing
G-to-A hypermutations in the viral genome [3,5,6]. How-
ever, Vif counteracts the activity of hA3G and hA3F and
prevents their encapsidation into virions by promoting
their proteasomal degradation via ubiquitination [7-9]. In
addition to the editing-mediated restriction by APOBEC3
deaminases, also other non-enzymatic inhibitory mechan-
isms have been described, some of which seem to be less
susceptible to inhibition by Vif [10,11]. Despite Vif expres-
sion, low levels of APOBEC3-mediated cytidine deamina-
tion are detectable, indicating that even wild-type HIV-1
can be restricted to some extent by the presence of APO-
BEC3 proteins [12,13]. Also, higher levels of A3G expres-
sion are able to overcome the effects of Vif [3,4,14],
suggesting that regulation of A3G expression may repre-
sent a novel target for antiretroviral therapy. In this regard,
several studies demonstrated regulation of APOBEC3 by
interferons or other immune mediators in vitro [15-22].
Several lines of evidence indicate that APOBEC3 may
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infected patients. First, a genetic variant of A3G was
reported that was associated with steeper CD4 T-cell
decline and faster disease progression in HIV-infected
African Americans [23]. Furthermore, APOBEC driven G-
to-A hypermutations in the viral genome occurring in vivo
during the early phase of HIV-1 infection also may have
an influence on disease progression by facilitating early
immune escape [24]. Finally, higher levels of A3G and
A3F were documented for HIV-1 infected individuals with
lower viral set points [25,26]. This finding however has
been challenged by other studies, which did not find a cor-
relation between hA3G and hA3F mRNA levels and viral
load [27].
Infection of macaques with simian immunodeficiency
viruses (SIV) is currently the best animal model to study
HIV infection and AIDS pathogenesis [28,29]. Although
experimental infection of rhesus macaques with SIV iso-
lates leads to disease and death in a shorter time-frame
compared with HIV infection, a similar variability in dis-
ease course with progressors and long term non progres-
sors (LTNP) has also been observed in SIV infection
[30,31]. Furthermore, it has been demonstrated that rhesus
APOBEC3 enzymes are also able to restrict SIV replication
[32] and that they are similarly degraded via Vif-dependent
mechanisms [33]. Taken together, the SIV rhesus macaque
model for AIDS provides the necessary components to
investigate the role of APOBEC3 for disease progression
under defined experimental settings. Therefore, we used
this model to determine A3G and A3F mRNA levels in
different cellular compartments. Levels of A3G and A3F
were correlated with viral load and disease progression. In
addition, we assessed a possible regulation of APOBEC3
through interferons in vivo by transcription analysis of
prototype interferon stimulated genes (ISGs).
Our results show significantly increased amounts of
A3G and A3F mRNA in SIV-infected asymptomatic maca-
ques with the highest APOBEC3 mRNA levels detected in
PBMC, purified CD4+ T-cells and CD14+ monocytes as
well as in peripheral lymph nodes of LTNPs. Furthermore,
we found an inverse correlation between APOBEC3
mRNA levels and viral load, suggesting a potential role of
APOBEC3 in reducing the viral load. Hence, our data in
the SIV rhesus macaque model strongly suggest a protec-
tive effect of APOBEC3 in the pathogenesis of AIDS. In
addition, we found evidence for a differential regulation of
APOBEC3 transcription in distinct disease stages.
Results
Increased APOBEC3 mRNA levels in asymptomatic SIV-
infected rhesus macaques
In order to study the impact of SIV infection on the
APOBEC3 transcription, we determined A3G and A3F
mRNA levels in 12 uninfected and 53 SIV-infected rhesus
macaques. Infected animals were grouped according to
their clinical stage. Twenty-nine macaques investigated
during the chronic disease stage were clinically asympto-
matic, whereas 24 macaques displayed signs of AIDS.
Our results show significantly increased levels of A3G
and A3F mRNA in peripheral blood mononuclear cells
(PBMC) of asymptomatic SIV-infected animals compared
with uninfected macaques and animals with AIDS (Figure
1A and 1B). In macaques with AIDS however, A3G and
A3F mRNA levels were not significantly different from
uninfected controls (Figure 1A and 1B). To further study
APOBEC3 levels in potential target cells, we purified CD4
+ T-cells and CD14+ monocytes with magnetic beads
from PBMC of a subset of animals. Compared with unin-
fected macaques, significantly increased A3F mRNA
levels were found in CD4+ T-cells of SIV-infected asymp-
tomatic animals (Figure 1D). Some asymptomatic SIV-
infected animals also showed high A3G mRNA levels
compared with uninfected controls, without reaching sig-
nificance (Figure 1C). Similar to PBMC and CD4+
T-cells, A3G and A3F mRNA levels in CD14+ monocytes
were elevated in SIV-infected asymptomatic animals
compared with uninfected macaques (Figure 1E and 1F).
This cell type could not be investigated in animals with
AIDS due to insufficient material. As a representative site
of major virus replication, we further quantified A3G and
A3F mRNA levels in peripheral and mesenteric lymph
nodes. Asymptomatic SIV-infected macaques also
showed a similar tendency to higher APOBEC3 mRNA
levels compared with uninfected animals, which however
failed to reach significance after post hoc correction for
multiple comparisons (Figure 1G-J). However, contrast-
ing the results from PBMC, animals with AIDS showed
even higher A3G mRNA levels in peripheral (Figure 1G)
and mesenteric lymph nodes (Figure 1I). Similar results
were obtained for A3F mRNA in mesenteric lymph nodes
of AIDS animals (Figure 1J).
Negative correlation of A3G and A3F mRNA with viral
load and disease progression
The high variation of APOBEC3 levels in SIV-infected
asymptomatic animals prompted us to look into a possi-
ble association with disease progression. Plasma viral
load represents the most common early predictor for dis-
ease progression in HIV-infected patients [34,35]. A com-
parable relationship between plasma viral load and SIV
infection has also been described in SIV-infected rhesus
monkeys [36]. Therefore, we correlated A3G and A3F
mRNA levels with plasma viral load. Our results showed
negative correlations between plasma viral load and A3G
and A3F mRNA levels in both total PBMC and purified
CD4+ T-cells (Figure 2A-D), which however was not sig-
nificant for A3G in the PBMC (Figure 2A). For the per-
ipheral lymph nodes, a negative correlation between A3G
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Figure 1 APOBEC3 mRNA levels in uninfected and SIV-infected macaques. A3G (left panels) and A3F (right panels) mRNA levels were
determined in uninfected (triangles) and SIV-infected animals with (diamonds) or without (circles) AIDS symptoms. Relative APOBEC3 mRNA
levels are shown in copy numbers per 100 copies of GAPDH in PBMC (A, B), CD4+ T-cells (C, D), CD14+ monocytes (E, F), lymphocytes from
peripheral (G, H) and mesenteric lymph nodes (I, J). Each data point represents one individual animal. Horizontal lines within the clusters are
depicting the median. Group comparisons were calculated using either the Kruskal-Wallis test with Dunn’s multiple comparison analysis for
PBMC, CD4+ T-cells and peripheral lymph nodes or the Mann-Whitney test for CD14+ monocytes (*p < 0.05; **p < 0.001). nd, not determined;
asymp., asymptomatic.
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Figure 2 Relationship of APOBEC3 mRNA levels and plasma viral load. A3G (left panels) or A3F (right panels) mRNA levels were correlated
with plasma viral load. Relative APOBEC3 mRNA levels are shown in copy numbers per 100 copies of GAPDH in PBMC (A, B), CD4+ T-cells (C, D)
and peripheral lymph nodes (E, F). Viral load is depicted as log-transformed RNA copies per millilitre (ml) plasma. r, Spearman’s correlation
coefficient; line shows nonlinear regression; p, P value; ns, not significant.
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Page 4 of 17and A3F mRNA levels and viral load was seen after
exclusion of symptomatic animals with AIDS (Figure 2E
and 2F). At necropsy sufficient material was available to
directly determine cell associated viral load in lymphoid
tissue, correlating well with viral RNA levels in plasma
(additional file 1). Cell associated viral load in lymph
node cells was inversely correlated with local A3G
mRNA levels (additional file 1).
This negative correlation between A3G and A3F expres-
sion and viral load found in PBMC, CD4+ T-cells and
peripheral lymph nodes suggests an association between
APOBEC3 expression and disease progression. Therefore,
we divided the SIV-infected asymptomatic macaques into
distinct groups according to their survival time, i )P r o -
gressors with a viral load above 10
4 copies per ml plasma
being asymptomatic without immunodeficiency when
investigated, but featuring a progressive disease course to
AIDS within three years post infection, and ii )L T N P s
representing asymptomatic animals, that had survived for
more than three years post infection in the absence of any
signs of immunodeficiency with a viral load below 10
4
copies per ml plasma when analysed. Our data demon-
strate significantly higher amounts of A3G and A3F in
PBMC (Figure 3A and 3B), CD4+ T-cells (Figure 3C and
3D) and in peripheral lymph node cells (Figure 3G and
3H) of LTNPs compared with progressor macaques. For
CD14+ monocytes, the difference in the APOBEC3
mRNA expression between LTNPs and progressors
was only significant for A3F (Figure 3F), but not for A3G
(Figure 3E). From a limited number of animals, we had
sufficient material to perform Western blot analysis of
A3G protein. Compared with uninfected control animals,
A3G expression in PBMC was strongly increased in LTNP
(additional file 2). Unfortunately, available antibodies
showed no cross-reactivity with rhesus monkey A3F.
Taken together, the negative correlation between APO-
BEC3 levels and viral load as well as the high APOBEC3
levels found in LTNPs, suggest a positive influence of
APOBEC3 on the disease course.
Positive correlation of ISG mRNA levels with viral load
and disease course
The increased expression of APOBEC3 in all cell types
investigated in asymptomatic animals, suggests a regula-
tion by infection specific factors. This is corroborated by a
coordinated expression of A3G and A3F, which was
observed in PBMC (p = 0.02), CD4+ T-cells (p = 0.02),
peripheral lymph nodes (p = 0.003) in SIV-infected maca-
ques. Possible candidates for this effect are interferons, as
they play an important role during viral infections. In addi-
tion, IFN-a has been shown to induce A3G expression in
human leukocytes through interferon response elements
(ISRE) in the A3G promotor [15,37]. Similarly, we
observed an IFN-a-induced, dose dependent increase of
A3G and A3F transcription in simian PBMC in vitro (data
not shown).
In order to investigate a potential influence of interfer-
ons on A3G and A3F levels in vivo, we quantified tran-
scription levels of two ISGs, MxA (myxovirus resistance 1)
and IP-10/CXCL10 (interferon-induced protein 10 kDa) as
they represent conventionally used surrogate markers for
interferon-mediated effects. Similar to A3G and A3F, we
found a significant increase in the MxA and IP-10 mRNA
levels in the PBMC of asymptomatic SIV-infected maca-
ques compared with uninfected animals. In macaques with
AIDS, MxA transcription levels were even higher than in
asymptomatic monkeys, although not reaching signifi-
cance (Figure 4A). IP-10 levels of all infected animals also
remained above those of uninfected macaques (Figure 4B).
This is in contrast to the results for A3G and A3F, where
transcription rates in PBMC were comparable between
animals with AIDS and uninfected controls (Figure 1A
and 1B). MxA- and IP-10-expression in SIV-infected ani-
mals was also elevated in CD4+ T-cells, CD14+ monocytes
and in both types of lymph nodes (data not shown). In
contrast to expression levels of A3G and A3F, which nega-
tively correlated with viral load, we found a positive corre-
lation between MxA or IP-10 mRNA levels and viral load.
Such an association was seen for both ISGs in PBMC
(Figure 4C and 4D), in CD4+ T-cells and in peripheral as
well as mesenteric lymph node cells, but only for MxA in
CD14+ monocytes (data not shown). By dissecting MxA
and IP-10 transcription of chronically infected rhesus
monkeys into those of progressors and LTNPs, we
observed lower mRNA levels of both ISGs in PBMC
(Figure 5A and 5B) and lower MxA levels in CD4+ T-cells
(Figure 5C) of LTNPs. Regarding the IP-10 mRNA levels
in the CD4+ T-cells, there was no significant difference
between progressors and LTNPs (Figure 5D). This was
also true for the ISGs mRNA levels in CD14+ monocytes
and in peripheral lymph nodes (Figure 5E-H).
These results, however, contrast the high A3G and
A3F mRNA levels found in LTNPs (Figure 3). Together
with the opposite correlations between plasma viral load
and APOBEC3 and ISGs mRNA levels respectively, this
may indicate a different regulation of A3G and A3F
than the prototype ISGs during asymptomatic phase.
A3G and MxA expression are increased during early SIV-
infection
Our results from the cross-sectional study suggest an
induction of A3G and A3F during the asymptomatic
phase of infection. Therefore, we followed the time
course of A3G and MxA levels during early infection.
Seven animals were inoculated with different doses of
S I Va sp a r to fa nin vivo titration study. All macaques,
except one of those inoculated with the lowest dose,
became infected and showed a typical course of plasma
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Figure 3 APOBEC3 mRNA levels in SIV-infected animals with different disease progression. A3G (left panels) and A3F (right panels) mRNA
levels were determined in SIV-infected progressors (open circles) or LTNPs (squares). Relative APOBEC3 mRNA levels are shown in copy numbers
per 100 copies of GAPDH in PBMC (A, B), CD4+ T-cells (C, D), CD14+ monocytes (E, F) and lymphocytes from peripheral lymph nodes (G, H).
Each data point represents one individual animal. Horizontal lines within the clusters are depicting the median. Group differences were
calculated using the Mann-Whitney test (*p < 0.05).
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Page 6 of 17viral load (Figure 6A). As shown previously, the inocula-
tion dose did not influence viral replication kinetics
in vivo [38]. This experiment was terminated early after
infection and animals were euthanized at predetermined
time points between six and 30 weeks post infection
without signs of AIDS. Figure 6 shows the kinetics of
A3G (B) and MxA transcription (C) for PBMC in these
macaques normalized to the mean of three independently
measured preinfection values. The inoculated macaque
that remained uninfected served as control. Starting one
week after infection, we observed a simultaneous increase
of A3G and MxA transcripts in PBMC compared with
preinfection values, which reached a maximum at ten
days post infection (Figure 6B and 6C). This was shortly
before peak viremia, which occurred at two weeks after
infection (Figure 6A). These variations were not seen in
the single animal that remained uninfected after inocula-
tion. After a nadir at two weeks post infection, the MxA
mRNA levels slightly increased again and remained sig-
nificantly elevated above preinfection values (Figure 6C).
Similarly, A3G mRNA decreased at two weeks post infec-
tion to levels only marginally above baseline, with a ten-
dency to a slow increase thereafter (Figure 6B). Due to
the limited number of animals, this rise, however, did not
reach significance in the observation period of this
experiment.
For some of the animals, it was also possible to quantify
A3G and MxA mRNA at certain time points after SIV
infection (either ten days or two weeks and six or 12
weeks post infection) in peripheral lymph nodes. By
including available preinfection data from some of the ani-
mals, it was possible to illustrate a kinetic for the periph-
eral lymph nodes as well (Figure 6D and 6E). Similar to
PBMC, we found significantly increased mRNA levels of
A3G and MxA during the acute phase, at ten days post
SIV infection. Later in the early asymptomatic phase, six
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Page 8 of 17to 12 weeks post SIV infection A3G and MxA mRNA
levels were reduced to almost normal levels (Figure 6D
and 6E).
Disease stage specific regulation of APOBEC3 expression
in vivo
The parallel kinetics of A3G and MxA expression suggest
common regulatory mechanisms for both genes at early
stages of infection. Indeed A3G and MxA transcription
was directly correlated in both PBMC and peripheral
lymph nodes during the acute phase (ten to 14 days post
infection) (Figure 7A and 7D). This contrasts the results
at later time points (12 to >156 weeks post infection) in
asymptomatic SIV-infected macaques, showing no or
even a negative correlation between MxA and A3G
mRNA level in PBMC and peripheral lymph nodes
(Figure 7B and 7E) or CD4+ T-cells (p = 0.132). Such
negative relationship was also found between IP-10 and
A3G in PBMC in the asymptomatic phase (p = 0.04).
Similar results were seen when comparing A3F with ISGs
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Page 9 of 17in all cell types investigated from asymptomatic animals
(data not shown). Interestingly in macaques with signs of
AIDS, levels of MxA and A3G (Figure 7C and 7F) or A3F
were again positively correlated in PBMC (p = 0.028) and
peripheral lymph nodes (p = 0.038). Such positive corre-
lations were also observed between IP-10 and A3G (p =
0.012 PBMC; p < 0.0001 peripheral lymph nodes) or A3F
(p = 0.04 PBMC; p = 0.044 peripheral lymph nodes) at
the time of necropsy.
These data suggest that several factors are involved in
the regulation of A3G and A3F during SIV infection.
The relative contribution of these different mechanisms
seems to vary with the stage of infection.
Discussion
Members of the APOBEC family of deaminases, such as
A3G and A3F, have been described as potent retrovirus
restriction factors, capable of inhibiting replication of
several viruses including HIV-1 in vitro [4,39-41]. In
rodents, it has been clearly demonstrated that APOBEC3
contributes to restriction of Friend MuLV infection in
vivo [42,43]. The role of APOBEC3 in the pathogenesis
of AIDS, however, is still under debate [24,25,27,44,45].
Therefore, we determined A3G and A3F transcription in
SIV-infected rhesus macaques and linked it to plasma
viral load and disease progression.
Compared with uninfected control animals, we found
increased mRNA levels of both A3G and A3F in SIV-
infected monkeys during the asymptomatic phase of the
disease. So far, several studies have investigated A3G
t r a n s c r i p t i o ni nH I V - i n f e c t e ds u b j e c t s ,h o w e v e rw i t h
inconsistent results [25-27,44,46,47]. Whereas some
reported increased levels of A3G in HIV-infected subjects
[25,44], others found lower A3G mRNA compared with
uninfected individuals [27,47]. In the few studies on A3F,
similarly discrepant results were observed [25,27]. Some
of the inconsistencies might be attributed to methodolo-
gical differences as both fresh and cryopreserved cells
with or without polyclonal stimulation were used. How-
ever, the wide variation between infected individuals, also
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Figure 7 Relationship between A3G and MxA mRNA levels during SIV disease stages. Relationship between relative A3G and MxA mRNA
levels in PBMC (A-C) and in peripheral lymph nodes (D-F) of SIV-infected asymptomatic macaques during acute infection (A and D, 10 to 14
dpi), in SIV-infected asymptomatic macaques during chronic infection (B and E, 12 to >156 wpi) and in SIV-infected macaques with AIDS (C and
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source of the conflicting data is likely differences in the
selection of patients with regard to disease stage and viral
load. In the present study, animals that had progressed to
AIDS had lower A3G and A3F levels in blood than
asymptomatic macaques. Although an association
between disease stage in humans and APOBEC3 tran-
scription has not been investigated explicitly, this is cor-
roborated by recent findings of very low A3G mRNA
levels in patients with CD4 counts below 200 [26]. On
the other extreme, as reported for HIV-patients [46], we
observed the highest mRNA levels among asymptomatic
animals in a group of LTNPs, representing animals that
had survived for more than three years after infection.
This association between APOBEC3 mRNA and disease
progression is substantiated by our finding of a negative
correlation between APOBEC3 levels and plasma viral
load. These results are in agreement with several previous
reports, which documented higher A3G [25,26,46] and
A3F [25] mRNA levels in PBMC of patients with lower
viral load. By contrast, another study did not find a corre-
lation between APOBEC3 mRNA and viral load [27]. As
observed previously [26], APOBEC3 mRNA copies in
individuals with high viral load were often below the
levels of uninfected controls. These findings may explain
the decreased A3G levels in PBMC of infected compared
with uninfected individuals reported by some studies,
probably due to differences in the composition of the
patient groups.
Our study is the first one, which quantified APOBEC3
mRNA in the context of an immunodeficiency virus
infection not only in whole PBMC, but also in leukocyte
subsets susceptible to infection such as CD4+ T-cells and
CD14+ monocytes as well as in the lymph nodes as
major virus replication sites. Despite slight variations, the
same tendencies were observed. A3G and A3F mRNA
levels correlated negatively with viral load and the highest
values were observed in LTNPs. Interestingly, the dichot-
omy in A3G transcription of individuals with higher or
with lower A3G levels than uninfected controls was more
pronounced in CD4+ T-cells possibly due to differences
in the cellular composition. In general, mRNA levels
determined in PBMC mirrored the situation in CD4+
T-cells or monocytes. However, this does not reflect the
conditions in lymph nodes. In lymph nodes from two dif-
ferent anatomical regions, we also detected high amounts
o fA 3 Ga n dA 3 Fm R N Ai nL T N P s .I nc o n t r a s tt ob l o o d
however, APOBEC3 levels in lymph nodes were still
increased in animals with AIDS. This might be explained
by the fact that AIDS-associated immunological altera-
tions occur later in lymphatic tissues than in blood
[48,49]. Since we sacrificed the animals when first signs
of AIDS appeared, the situation in lymph nodes may still
be more similar to the asymptomatic phase. Also
differences in the cellular composition or in the microen-
vironment between the different compartments [50]
could be responsible as APOBEC3 transcription varies
between different cell types and tissues [21,51,52] and
can be influenced by interferons, cytokines and chemo-
kines [17,19,20,22,37,51]. To our knowledge, APOBEC3
mRNA in lymph nodes of HIV-patients has yet not been
studied to substantiate our results with findings from the
human setting.
Our data clearly demonstrate a negative correlation of
A3G and A3F mRNA levels with viral load and an asso-
ciation of high A3G and A3F mRNA levels with pro-
longed survival, suggesting a possible effect of APOBEC3
on viral replication in vivo favorably influencing disease
progression. It has been hypothesized, that the higher
A3G levels in LTNPs or patients with low viral load are
due to preexisting differences in gene expression [45].
However, our longitudinal studies suggest that A3G tran-
scription is actually up-regulated after infection. This is
in line with the results of a recent publication where
A3G transcription was compared in the same individuals
before and after infection [25]. In addition, we found
coordinated transcription of A3G and A3F in all cell
populations investigated only in SIV-infected animals,
which points to common regulatory mechanisms induced
by the infection. Interestingly, increased A3G levels have
also been reported in patients with HCV-infection [53].
General to viral infections is a potent induction of type
one interferons and several studies have demonstrated
stimulation of A3G and A3F expression by interferons
in vitro [15,37,54,55]. Therefore, we have determined the
transcription of conventionally used prototype inter-
feron-stimulated genes to assess interferon activity in our
animals. As reported previously for both HIV-infected
humans and SIV-infected macaques [56-58], we observed
an early and strong rise of MxA mRNA, which reached
its maximum ten days after infection, hence preceding
peak viral load. This up-regulation of ISG was paralleled
by a more moderate increase in A3G mRNA levels. With
resolution of peak viremia both MxA and A3G levels
declined but remained slightly above preinfection levels
in both PBMC and lymph node cells. These parallel
kinetics indicate that APOBEC3 deaminases are down-
stream effector molecules of a type I interferon response
in acute viral infections. In the chronic phase of SIV-
infection, however, we found a divergent expression of
prototype ISG and A3G/A3F. Whereas MxA and IP-10
transcription increased with higher viral replication, A3G
and A3F mRNA levels were negatively correlated with
plasma viral load in SIV-infected asymptomatic animals.
Thus, other mechanisms must be responsible for the
higher APOBEC3 levels found in asymptomatic animals,
especially in LTNPs. As acute phase and end stage
disease are characterized by a lack of virus specific
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response than progressors [59], mediators associated
with a potent immune reaction are likely candidates for
this additional APOBEC3 modulation in asymptomatic
animals. Cytokines like IL-2 and IL-15 have been shown
to induce A3G expression in vitro [19,22], PBMC from
LTNPs produce higher amounts of IL-2 [60] and adju-
vanting vaccine vectors with IL-15 improves protection
against pathogenic challenge in the SIV/macaque model,
partly through an induction of A3G [22]. In this context
it would be interesting to explore the effect of HAART
on APOBEC3 levels as effective antiretroviral treatment
has been shown to restore IL-2 production by antigen
specific cells [61] and IL-15 levels correlated with better
outcome of structured treatment interruption [62]. In
addition, it has been reported that cross-talk between
dendritic cells and T-cells also results in the induction of
A3G expression by both contact dependant mechanisms
via CD40-CD40L interaction and through soluble media-
tors such as IL-15 [17]. Dendritic cells are depleted in
progressive HIV-infection [63], but accumulate in lymph
nodes of LTNPs exhibiting elevated CD40 expression
[64]. Increased signaling through CD40 ligand may thus
be responsible for the higher A3G expression in the
asymptomatic phase. Consistent with the reported loss of
CD40 expressing dendritic cells in AIDS patients [64],
this regulatory pathway attenuates leading to the lower
APOBEC3 transcription, which we observed in PBMC of
animals with symptoms of AIDS. At this stage of the
infection, A3G and A3F mRNA levels once again seem to
be governed solely by interferons as they correlated with
the transcription of ISGs.
An alternative explanation for the disease stage specific
relationship between APOBEC3 and ISG expression could
be shifts in the composition of cells. Some groups have
reported a stronger induction of A3G and A3F transcrip-
tion by IFN-alpha for macrophages compared with CD4+
T-cells [21,51,55] and for resting compared with activated
CD4+ T-cells [15]. However, as we see the same disease
s t a g es p e c i f i cp a t t e r nf o ra l lcell types investigated, such
differences in sensitivity to interferon stimulation probably
do not contribute to the discrepancy between APOBEC3
and ISG transcription in asymptomatic animals.
In summary, we think that increased amounts of inter-
ferons in SIV-infected macaques influence APOBEC3
mRNA levels throughout the infection. However, as evi-
denced by the much lower induction of A3G during peak
viremia compared with prototype ISG, the effect of inter-
ferons on the transcriptional control of APOBEC3 dea-
minases in vivo is moderate. This interferon-mediated
basic regulation is then overlaid by additional modulatory
mechanisms, which need time to build up and are stron-
gest in LTNPs, but ultimately vanish during AIDS. Such
mechanisms may also potentially become activated in
uninfected individuals as various vaccination regimens
can induce a long lasting upregulation of A3G in maca-
ques [22,65]. In addition, several studies have documen-
ted increased A3G mRNA levels in HIV-1 exposed but
seronegative individuals [26,44], who are known to
mount a subtle HIV-specific cellular immune response
[66]. Interestingly, cessation of exposure was associated
with both decreased A3G levels [26] and with a loss of
anti-HIV-1 T-cell response [67]. Exploring the mechan-
isms leading to increased APOBEC3 levels in LTNPs or
HIV-1 exposed but seronegative individuals should pro-
vide useful information for new therapeutic approaches.
The results from this and previous studies suggest that
increased APOBEC3 mRNA levels are associated with
lower viral load and slower disease progression. According
to our data, A3G and A3F mRNA levels are increased also
in CD4+ lymphocytes and CD14+ monocytes, the cellular
targets of HIV, and in lymph nodes where the majority of
CD4+ T-cells resides and where abundant viral replication
takes place. Information on other tissues with high viral
load such as mucosa associated lymphoid tissue is sparse.
So far, only cervical biopsies have been investigated where
A3G levels were comparable between infected and unin-
fected individuals [44].
Evidence that APOBEC3 actually exerts its deaminase
activity in vivo is derived from studies, which found the
typical G to A mutations imprinted on the viral genomes
in HIV-infected patients [12,26,68]. The extent of these
characteristic mutations correlated with A3G transcription
[26], indicating that increased APOBEC3 expression may
overcome the restraints imposed by Vif [2]. Moreover,
higher hypermutation rates conforming to the A3G and
A3F sequence preferences were associated with lower viral
load and higher CD4 cell counts [12,68]. On the other
hand, increased A3G/A3F expression may be beneficial
even without demonstrable hypermutations as APOBEC3
enzymes can restrict viral replication through mechanism
distinct from cytidine deamination [10,11,69].
Conclusions
By demonstrating an association between increased A3G
and A3F mRNA levels with prolonged survival in the
defined experimental setting of an animal model, we pro-
vide further evidence for a potential protective role of
APOBEC3 in the pathogenesis of HIV-infection. Depend-
ing on the stage of the infection, several mechanisms seem
to contribute to the up-regulation of APOBEC3 transcrip-
tion in vivo. We postulate that A3G is regulated in vivo by
type I interferons, an effect which appears to dominate in
the acute and AIDS phases. In addition, there are other
regulatory mechanisms, most strongly present in LTNP,
which govern APOBEC regulation in the asymptomatic
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mechanism may help to exploit these intrinsic antiretro-
viral factors for anti-HIV therapy and vaccination.
Materials and methods
Animals
Rhesus macaques (Macaca mulatta) of Indian origin were
housed at the German Primate Centre under standard
conditions according to the German animal protection
law which complies with the European Union guidelines
on the use of non-human primates for biomedical
research. Animals were infected either via the tonsils with
SIVmac239 [70] or intravenously with a SIVmac251-
derived virus stock [71], both prepared in rhesus monkey
peripheral blood mononuclear cells. Sampling of blood
was carried out under ketamine anesthesia. For sampling
of lymph nodes, the animals were anesthetized with a mix-
ture of 5 mg ketaminhydrochloride, 1 mg xylazinhy-
drochloride and 0.01 mg atropine sulfate per kg body
weight. Mesenteric lymph nodes were obtained on the day
of necropsy.
In a cross-sectional study, 53 infected animals were
grouped according to their clinical stage. Twenty-nine
macaques, which were clinically asymptomatic, were
investigated during the chronic phase of the infection.
Some of these were sacrificed according to the experimen-
tal schedule without signs of AIDS. 24 macaques were
euthanized when first signs of AIDS appeared, i.e. anor-
exia, incurable diarrhoea, Pneumocystis jirovecii infection
or neurological dysfunction as judged from clinical as well
as necropsy and histopathological findings, which were
available for each macaque (additional file 3).
Blood and/or lymph node samples were obtained at dif-
ferent time points after infection ranging from 12 to >156
weeks post infection (wpi) for SIV-infected asymptomatic
macaques (median 62 wpi) and 22 to 138 wpi for animals
with AIDS (median 80 wpi). Ten of the asymptomatic ani-
mals survived with a set point viremia of below 10
4 RNA
copies/ml plasma for more than three years and were thus
regarded as LTNP. The remaining asymptomatic animals
had viral loads above 10
4 RNA copies/ml plasma at
the time of investigation and later showed a progressive
disease course leading to AIDS within three years of
infection.
Equal numbers of animals had been infected with SIV-
mac239 or SIVmac251 and mRNA levels of A3G, A3F,
MxA and IP-10 were not influenced by the infecting virus
strain. 12 uninfected clinically healthy rhesus macaques
were used as negative control group.
In a longitudinal study, two animals were inoculated
intravenously with 100 TCID50, three animals with 10
TCID50 and two animals with 1 TCID50 of SIVmac251 as
part of an in vivo titration experiment aimed at defining
the in vivo infective dose of a new monkey PBMC-derived
virus stock. This SIVmac251 challenge virus was prepared
on PHA-stimulated PBMC from several monkeys using
SIVmac251 [71] as inoculum. Supernatants were harvested
and pooled. After filtration, aliquots were prepared and
stored at -140C and the TCID50 was determined on
C8166 cells.
Lymphocyte isolation
Peripheral blood was collected by venipuncture and per-
ipheral blood mononuclear cells (PBMC) were isolated via
ficoll-paque gradient centrifugation (lymphocyte separa-
tion medium, PAA laboratories, Pasching, Austria). PBMC
were washed with phosphate-buffered saline (PBS). CD4+
T-cells and CD14+ monocytes were enriched from fresh
PBMC by positive selection using magnetic beads (Milte-
nyi Biotec, Bergisch-Gladbach, Germany) and monoclonal
antibodies to either CD4 or CD14. The purity of the iso-
lated CD4+ T-cells and CD14+ monocytes were analyzed
by flow cytometry on a LSR II flow cytometer (Becton
Dickinson, Heidelberg, Germany) with the following fluor-
escence conjugated antibodies: anti-CD3 Alexa 700 (BD
Biosciences); anti-CD4 Alexa 405 (BD Biosciences), anti-
CD14 PerCP Cy5.5 (BD Biosciences), anti-CD20 PECy 7
(BD Biosciences) and anti-CD45 FITC (Mitenyi Biotec).
Only CD4+ T-cells and CD14+ monocytes with purity
above 90% were used for downstream applications. Tissue
cell suspensions from lymph nodes were prepared by
dissecting the lymph nodes with scalpels and forceps
in RPMI 1640 (PAN Biotech, Aidenbach, Germany) sup-
plemented with 10% FCS (PAN Biotech, Aidenbach,
Germany), 100 U/ml penicillin (PAN Biotech, Aidenbach,
Germany) and 100 μg/ml streptomycin (PAN Biotech,
Aidenbach, Germany) (complete RPMI) and passing the
homogenate through a cell strainer (100 μmn y l o n ;B D
Biosciences, Heidelberg, Germany). Separated cells were
washed twice in PBS and living cells were counted by try-
pan blue exclusion.
RNA isolation and cDNA synthesis
Total cellular RNA was isolated from 2 × 10
6 to 5 × 10
6
cells with the RNeasy Plus Mini Kit (Qiagen, Hilden,
Germany), according to the manufacturer’s instructions.
Purified RNA was quantified by measuring the optical
density at 260 nm (OD260). All samples had an OD260/
OD280 ratio of 1.9 or greater. The quality of the isolated
RNA was randomly checked by Agilent 2100 Bioanalyzer
(Agilent Technologies, Böblingen, Germany) featuring
RIN values (RNA Integrity Number) of at least 8.0. Synth-
esis of cDNA was carried out with random hexamer pri-
mers and SuperScript III First-Strand Synthesis System for
RT-PCR kit (Invitrogen Gmb H ,K a r l s r u h e ,G e r m a n y ) ,
according to the manufacturer’s protocol.
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We established a real-time PCR assay to quantify A3G,
A3F, MxA and IP-10/CXCL10 mRNA levels in lympho-
cytes/leukocytes using SYBR Green (Qiagen, Hilden,
Germany) chemistry with primers designed to uniquely
amplify A3G (Genbank accession number AY331716), A3F
(Genbank accession number NM_001042373), MxA
(Genbank accession number EF101561) and IP-10/
CXCL10 (Genbank accession number AY044446). The fol-
lowing primers (Sigma, Hamburg, Germany) were used:
A3G forward, 5’-TCTACGCAACCAGGCTCCA-3’ (nt 702
to 720); A3G reverse 5’-GGAATCAGGTCCAGGAAGCA-3’
(nt 779 to 760); A3F forward, 5’-CAGTAATGTGAAGCT
CGCCATC-3’ (nucleotides [nt] 882 to 903); A3F reverse,
5’-TGCTGGTAATGTGTATCCCAGAA-3’ (nt 947 to 925);
MxA forward, 5’-AGGAGTTGCCCTTCCCAGA-3’ (nt 295
to 313); MxA reverse, 5’-TCGTTCACAAGTTTCTTCAG
TTTCA-3’ (nt 372 to 348); IP-10/CXCL10 forward, 5’-
GATTTGCTGCCTTGTCTTTCTGA-3’ (nt 21 to 43); IP-10/
CXCL10 reverse, 5’-CAGGTACAGCGTACAGTTCTTGAGA-
3’ (nt 95 to 71). Primers were selected in less conserved
regions to limit sequence homologies with other APOBEC3
genes. Later, significant homology was detected in the A3F
primer region with A3D, a sequence which was not avail-
able at the beginning of the study. Sequences for the MxA
primers were taken from Abel et al. [72]. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (Genbank accession
number XM_001105471) was used as a house keeping gene
with the following primers taken from Rodriguez-Jimenez
et al. forward, 5’-CCTGCACCACCAACTGCTTA-3’(nt 525
to 544); reverse, 5’-CATGAGTCCTTCCACGATACCA-3’
(nt 598 to 577) [73]. The reactions were performed in
Micro Amp optical tubes or plates (Applied Biosystems
GmbH, Darmstadt). Each 25 μl reaction mixture contained
12.5 μl 2 × QuantiTect SYBR Green PCR master mix (Qia-
gen, Hilden, Germany), 1 μlo fe a c h1 0μM primer, and 2 μl
cDNA products. The reactions were run in an ABI Prism
7500 with one cycle at 95°C (15 min) followed by 40 cycles
at 95°C (15 s) and 55°C (1 min). Validation experiments
were performed to determine the specificity and efficiency
of the primers to selectively amplify the target gene. Melt-
ing curves and agarose gel documentation demonstrated
the existence of a single product (additional file 4). The cal-
culated efficiency for all primers, determined by dilution
experiments, was from 97% to 99 %, thus target sequences
were amplified with similar efficiencies. All samples were
run at least in duplicates. The results were analyzed by
Sequence Detection Software (Applied Biosystems GmbH,
Darmstadt), and A3F, A3G, MxA and IP-10/CXCL10
mRNA levels were calculated as copy numbers relative to
100 copies of GAPDH.
Western blot for APOBEC3G protein
PBMCs were lysed with ice-cold buffer containing 50
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH 7.4, 150 mM NaCl, 0.1% octyl phenoxylpo-
lyethoxylethanol (Nonidet-P40), 0.5 mM phenylmetha-
nesulfonylfluoride (PMSF), 1% protease inhibitor
cocktail (Sigma, Hamburg, Germany). Proteins were
quantified by a bicinchoninic acid protein assay reagent
kit (Pierce, Rockford, USA). An equal amount of protein
(20 μg) from different animal samples was loaded in
individual lanes of a 12% SDS-polyacrylamide gel. After
electrophoretic separation, the proteins were transferred
to nitrocellulose membrane (Schleicher & Schuell
Bioscience, UK). Membranes were blocked with 5% milk
powder phosphate-buffered saline with 0.1% Tween-20
and probed with monoclonal anti-APOBEC3G at 1:1000
(Immunodiagnostics, Woburn, MA, USA) at 4°C over-
night. Membranes were washed with phosphate-buffered
saline with 0.1% Tween-20 three times for 5 minutes
and incubated for one hour with secondary antibody
conjugated with horseradish proxidase (Jackson Immu-
noResearch, Suffolk, UK) and detected by chemilumi-
nescence (Super Signal West Pico Chemoluminescence
Kit Pierce, Rockford, USA).
Quantification of Plasma viral RNA and cell associated
viral load
Isolation of viral RNA was performed from plasma samples
according to the MagAttract Virus Mini M48 protocol
(Qiagen, Hilden, Germany). Purified SIV RNA was quanti-
fied with TaqMan-based real-time PCR on an ABI-Prism
7500 sequence detection system (Applied Biosystems
GmbH, Darmstadt) as described [74]. Amplified viral RNA
was calculated as SIV-RNA copies per millilitre plasma.
Cell associated viral loads in organs were determined
by limiting dilution coculture of monkey PBMC and the
permanent T-cell C8166 as indicator cells, which were
adhered to concanavalin A-coated microtiter plates.
Viral replication in cultures was visualized by immuno-
peroxidase staining of intracellular antigen [50].
Statistics
The statistical analyses were calculated with GraphPad
Prism version 5 (GraphPad software). For interpretation
between more than two groups the Kruskal-Wallis test
with Dunn’s multiple comparison analysis was used and
for comparison between two groups the nonparametric
two tailed Mann-Whitney’s U test were used. For corre-
lation the nonparametric two tailed Spearman test was
performed. Significance level was always set at p-values
less than 0.05.
Additional material
Additional file 1: Correlation of cell associated viral load in LN with
plasma viral load and LN A3G mRNA levels. Two figures depicting a
significant association between cell associatiated viral load in LNmes and
viral RNA levels in plasma and A3G mRNA levels in LNmes respectively.
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Page 14 of 17Additional file 2: Western blot of A3G protein. Western blot analysis
of PBMC shows higher levels of A3G protein in LTNP than uninfected
animals.
Additional file 3: Major clinical and pathological findings in animals
with AIDS. Table listing major clinical and pathological findings in
individual animals.
Additional file 4: Melting curves and gel electrophoresis of A3G and
A3F PCR products. Melting curves and gel documentation shows single
products of PCR reactions with A3G and A3F primers.
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